Abstract
To evaluate the efficacy and tolerability of 'Casodex' monotherapy (150 mg daily) for metastatic and locally advanced prostate cancer.
| Original language | English |
|---|---|
| Journal | European Urology |
| Volume | 33 |
| Issue number | 5 |
| Pages (from-to) | 447-56 |
| Number of pages | 10 |
| ISSN | 0302-2838 |
| Publication status | Published - 1998 |
Keywords
- Aged
- Aged, 80 and over
- Androgen Antagonists
- Anilides
- Bone Neoplasms
- Castration
- Humans
- Male
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Staging
- Nitriles
- Probability
- Prognosis
- Prostate-Specific Antigen
- Prostatic Neoplasms
- Quality of Life
- Survival Rate
- Tosyl Compounds
- Treatment Outcome
Fingerprint
Dive into the research topics of 'A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS